Impact of intensive lipid modulation on angiographically defined coronary disease: Clinical implications

Robert W. Paterson, John J. Paat, George H. Steele, Sharon C. Hathaway, Jeffrey G. Wong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We reviewed all randomized, controlled angiographic trials to assess the impact of intensive lipid modulation on the progression or regression of angiographically defined coronary disease. Five of seven trials satisfied selection criteria: Cholesterol- Lowering Atherosclerosis Study, Program on the Surgical Control of the Hyperlipidemias, Familial Atherosclerosis Treatment Study, Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia, and St. Thomas’ Atherosclerosis Regression Study. We compared patient selection, baseline and on-trial lipid values, changes in angiographic disease scores, and clinical outcomes. In all five trials, treatment reduced levels of low-density lipoprotein (LDL) cholesterol substantially (range -32% to -46%). Treatment reduced risk of angiographic progression by almost 50% compared to controls. Furthermore, nearly one third of drug-treated patients showed angiographic regression of disease. Regression correlated well with reduction in LDL cholesterol. Although overall improvement in stenosis was modest, reduction in clinical events was impressive. Intensive lipid modulation may “stabilize” existing lesions, making them less “active” (ie, less prone to rupture or thrombosis), thereby reducing risk of acute coronary syndromes. These studies clearly support intensive lipi< established modulation in patients with coronary disease.

Original languageEnglish (US)
Pages (from-to)236-242
Number of pages7
JournalSouthern Medical Journal
Volume87
Issue number2
DOIs
StatePublished - Feb 1994

Fingerprint

Coronary Disease
Lipids
Atherosclerosis
LDL Cholesterol
Patient Selection
Hyperlipoproteinemia Type II
Therapeutics
Acute Coronary Syndrome
Hyperlipidemias
Coronary Artery Disease
Rupture
Pathologic Constriction
Thrombosis
Randomized Controlled Trials
Cholesterol
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Paterson, Robert W. ; Paat, John J. ; Steele, George H. ; Hathaway, Sharon C. ; Wong, Jeffrey G. / Impact of intensive lipid modulation on angiographically defined coronary disease : Clinical implications. In: Southern Medical Journal. 1994 ; Vol. 87, No. 2. pp. 236-242.
@article{9a9f7284a2eb4535a947c39439cfc423,
title = "Impact of intensive lipid modulation on angiographically defined coronary disease: Clinical implications",
abstract = "We reviewed all randomized, controlled angiographic trials to assess the impact of intensive lipid modulation on the progression or regression of angiographically defined coronary disease. Five of seven trials satisfied selection criteria: Cholesterol- Lowering Atherosclerosis Study, Program on the Surgical Control of the Hyperlipidemias, Familial Atherosclerosis Treatment Study, Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia, and St. Thomas’ Atherosclerosis Regression Study. We compared patient selection, baseline and on-trial lipid values, changes in angiographic disease scores, and clinical outcomes. In all five trials, treatment reduced levels of low-density lipoprotein (LDL) cholesterol substantially (range -32{\%} to -46{\%}). Treatment reduced risk of angiographic progression by almost 50{\%} compared to controls. Furthermore, nearly one third of drug-treated patients showed angiographic regression of disease. Regression correlated well with reduction in LDL cholesterol. Although overall improvement in stenosis was modest, reduction in clinical events was impressive. Intensive lipid modulation may “stabilize” existing lesions, making them less “active” (ie, less prone to rupture or thrombosis), thereby reducing risk of acute coronary syndromes. These studies clearly support intensive lipi< established modulation in patients with coronary disease.",
author = "Paterson, {Robert W.} and Paat, {John J.} and Steele, {George H.} and Hathaway, {Sharon C.} and Wong, {Jeffrey G.}",
year = "1994",
month = "2",
doi = "10.1097/00007611-199402000-00018",
language = "English (US)",
volume = "87",
pages = "236--242",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Impact of intensive lipid modulation on angiographically defined coronary disease : Clinical implications. / Paterson, Robert W.; Paat, John J.; Steele, George H.; Hathaway, Sharon C.; Wong, Jeffrey G.

In: Southern Medical Journal, Vol. 87, No. 2, 02.1994, p. 236-242.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of intensive lipid modulation on angiographically defined coronary disease

T2 - Clinical implications

AU - Paterson, Robert W.

AU - Paat, John J.

AU - Steele, George H.

AU - Hathaway, Sharon C.

AU - Wong, Jeffrey G.

PY - 1994/2

Y1 - 1994/2

N2 - We reviewed all randomized, controlled angiographic trials to assess the impact of intensive lipid modulation on the progression or regression of angiographically defined coronary disease. Five of seven trials satisfied selection criteria: Cholesterol- Lowering Atherosclerosis Study, Program on the Surgical Control of the Hyperlipidemias, Familial Atherosclerosis Treatment Study, Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia, and St. Thomas’ Atherosclerosis Regression Study. We compared patient selection, baseline and on-trial lipid values, changes in angiographic disease scores, and clinical outcomes. In all five trials, treatment reduced levels of low-density lipoprotein (LDL) cholesterol substantially (range -32% to -46%). Treatment reduced risk of angiographic progression by almost 50% compared to controls. Furthermore, nearly one third of drug-treated patients showed angiographic regression of disease. Regression correlated well with reduction in LDL cholesterol. Although overall improvement in stenosis was modest, reduction in clinical events was impressive. Intensive lipid modulation may “stabilize” existing lesions, making them less “active” (ie, less prone to rupture or thrombosis), thereby reducing risk of acute coronary syndromes. These studies clearly support intensive lipi< established modulation in patients with coronary disease.

AB - We reviewed all randomized, controlled angiographic trials to assess the impact of intensive lipid modulation on the progression or regression of angiographically defined coronary disease. Five of seven trials satisfied selection criteria: Cholesterol- Lowering Atherosclerosis Study, Program on the Surgical Control of the Hyperlipidemias, Familial Atherosclerosis Treatment Study, Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia, and St. Thomas’ Atherosclerosis Regression Study. We compared patient selection, baseline and on-trial lipid values, changes in angiographic disease scores, and clinical outcomes. In all five trials, treatment reduced levels of low-density lipoprotein (LDL) cholesterol substantially (range -32% to -46%). Treatment reduced risk of angiographic progression by almost 50% compared to controls. Furthermore, nearly one third of drug-treated patients showed angiographic regression of disease. Regression correlated well with reduction in LDL cholesterol. Although overall improvement in stenosis was modest, reduction in clinical events was impressive. Intensive lipid modulation may “stabilize” existing lesions, making them less “active” (ie, less prone to rupture or thrombosis), thereby reducing risk of acute coronary syndromes. These studies clearly support intensive lipi< established modulation in patients with coronary disease.

UR - http://www.scopus.com/inward/record.url?scp=0028295837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028295837&partnerID=8YFLogxK

U2 - 10.1097/00007611-199402000-00018

DO - 10.1097/00007611-199402000-00018

M3 - Article

C2 - 8115891

AN - SCOPUS:0028295837

VL - 87

SP - 236

EP - 242

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 2

ER -